Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from 'Senescence surveillance of pre-malignant hepatocytes limits liver cancer development' by Kang et al. (2011) , published in Nature in 2011. The experiments that will be replicated are those reported in Figures 3B, 3C, 3E , and 4A. In these experiments, Kang et al. (2011) demonstrate the phenomenon of oncogene-induced cellular senescence and immunemediated clearance of senescent cells after intrahepatic injection of NRAS ( Figures 2I, 3B, 3C , and 3E). Additionally, Kang et al. (2011) show the specific necessity of CD4+ T cells for immunoclearance of senescent cells ( Figure 4A ).
Introduction
Cellular senescence-a permanent state of proliferative arrest-has been shown to be an important failsafe mechanism against tumor development in vivo. Aberrant activation of oncogenes can force normal cells into a senescent state of stable cell cycle arrest (Narita and Lowe, 2005) . Senescence is often associated with a pre-malignant state, and a wide range of cancers have been shown to harbor populations of senescent cells (Quintanilla et al., 1986; Braig et al., 2005; Collado et al., 2005; Bennecke et al., 2010 ). An ongoing debate in the field of cancer biology has been the phenomenon of 'immune surveillance', or the ability of the immune system to specifically identify and eliminate nascent precancerous (e.g., senescent) cells before they can cause harm (Swann and Smyth, 2007) . The possibility of tailored, pro-senescent therapies for cancer treatment has provoked considerable interest. Kang et al. (2011) report that pre-malignant, senescent hepatocytes are recognized and cleared through a CD4 + T-cell-specific immune response and that this immunosurveillance is crucial for tumor suppression in vivo. The authors attempted to mimic aberrant oncogene activation by stably delivering oncogenic Nras G12V into mouse livers in vivo. Hydrodynamic injection of transposable elements resulted in mosaic generation of Nras-expressing hepatocytes that displayed senescent markers. Time course analyses revealed a progressive loss of Nras G12V expressing senescent cells within 2 months after stable intrahepatic delivery of oncogenic Nras
G12V
. Studies were carried out in wild-type mice, as well as immunocompromised mice (SCID/beige and CD4 −/− ). Importantly, all analyses were paralleled using an Nras G12V effector loop mutant (Nras
G12V/D38A
) incapable of signaling to downstream pathways (Kang et al., 2011) . In Figures 2I, 3B , 3C, and 3E, Kang et al. (2011) tested whether intrahepatic expression of oncogenic Nras G12V induced cellular senescence in affected hepatocytes (as indicated by the expression of pro-senescent markers p16 and p21), and if senescent cells were eventually cleared over a time course spanning 60 days. Further, Kang et al. demonstrated the necessity of a functional adaptive immune response in clearing senescent cells, as mice harboring mutations in adaptive immunity (SCID/beige) showed significant attenuation in the ability to clear pre-malignant cells. These key experiments, which test the major underlying hypotheses of the paper, are replicated with Protocol 1. In Figure 4A , Kang et al. demonstrated the specific necessity of CD4 + T lymphocytes in undertaking senescence surveillance. They showed that CD4 −/− mice displayed significantly abrogated clearing of Nras-positive hepatocytes 12 days following intrahepatic injection of NrasG12V; no immunoclearance was observed for either CD4 −/− mice or wild-type controls expressing the defective signaling mutant NrasG12V/D38A. These key results suggest that an intact CD4 + T-cell-mediated adaptive immune response is necessary for senescence surveillance of pre-malignant hepatocytes. These experiments will be replicated in Protocol 2.
To date, conflicting reports of Ras-associated senescence have been reported. Using a mouse model with conditional pancreatic expression of Kras, Kennedy et al. (2011) demonstrated that activated KrasG12D-induced senescence in pancreatic cells. However, using an intrahepatic injection system similar to Kang et al., Ho et al. (2012) did not detect positive markers for senescence in the livers of Nrasinjected wild-type mice as compared to controls. Multiple studies have observed immunoclearance of senescent cells similar to results reported by Kang et al. Xue et al. (2007) reported rapid clearance of senescent cells by the immune system, and Rakhra et al. (2010) reported similar findings, as well as demonstrating that CD4 + T cells were necessary for clearing senescent cells. Similarly, Acosta et al. (2013) demonstrated clearance of Nras-positive cells in wild-type mice, but impaired clearance in mice treated with various immunosuppressive drugs. Interestingly, co-injection of NrasG12V along with other oncogenes failed to manifest senescence surveillance, and instead resulted in an aggressive tumor phenotype (Brinkhoff et al., 2014) . Likewise, intrahepatic activation of SV40 large T antigen resulted in hepatocellular carcinoma development and did not activate immunosurveillance (Willimsky and Blankenstein, 2005) .
Materials and methods
Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterix (*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (#) indicates information provided by the replicating lab.
Protocol 1: generation of oncogene-induced senescence and immunosurveillance in murine hepatocytes
This protocol assesses whether intrahepatic expression of oncogenic Nras G12V induces cellular senescence, and if such pre-malignant senescent hepatocytes are eventually eradicated over time, as is depicted in Figures 2I, 3B , 3C, and 3E. This protocol also determines the necessity of a functional adaptive immune response in clearing senescent cells by measuring the abrogation of Nras-, p21-, and p16-positive hepatocytes in severely immune-compromised mice (SCID/beige) injected with either Nras G12V or Nras G12V/D38A .
Sampling
• These experiments will analyze a minimum of five mice per treatment group, for a total power of between 89.8% and 99.9%.
1. See 'Power calculations' section for details. 2. In order to account for variability in hydrodynamic injections that might contribute to exclusion of study animals (estimated as a 20% failure rate by Kang et al.) , the initial starting sample size will be seven mice per treatment group. The inclusion of two additional animals will help ensure that at least five animals are available for analysis at the conclusion of the study.
• Outline of experimental conditions:
1. Mouse Cohort 1 (tissue processed at 6 days post-injection).
• 14 female C.B-17 wild-type mice (4-6 weeks old).
a. Seven mice injected with pPGK-SB13 + pT/CaggsNras • 14 female C.B-17 wild-type mice (4-6 weeks old). 
The following procedures (steps 1-5) are presented in greater detail in Bell et al. (2007) . Please consult this resource for enhanced experimental protocol detail and description.
1. Grow and prepare endotoxin-free plasmid constructs according to the manufacturer's protocol for the GenElute Endotoxin-free Plasmid Maxiprep Kit. Store DNA at ∼1-2 µg/µl in 10 mM Tris-HCl, pH 7.2, 0.1 mM ethylenediaminetetraacetic acid (EDTA) at 4°C.
a. Prepare >400 µg of pPGK-SB13 transposase vector. b. Prepare >1000 µg of pT/CaggsNras G12V transposon vector. c. Prepare >1000 µg of pT/CaggsNras G12V/D38A transposon vector.
2. Sequence plasmids to confirm identity and run on gel to confirm vector integrity, as well as Nras mutational status.
a. Use the following pT/CaggsNras sequencing primers:
i. Forward: tgtgaccggcggctctaga. ii. Reverse: cgaggctgatccttgaaagtggctctt.
3. Obtain 4-week-old female C.B-17 wild-type and C.B-17 SCID/beige mice.
a. Mice should be randomized into strain-based treatment and control groups and co-housed so that mice of the same strain receiving either Nras G12V or Nras G12V/D38A injections are housed together. b. House mice in ventilated cages (IVC) that are specific pathogen free (SPF). Allow mice 1 week to acclimate to new housing prior to injection.
4. Prepare 5-week-old mice for injection.
a. Mix anesthetic cocktail: 8 mg/ml ketamine HCl, 0.1 mg/ml acepromazine maleate, and 0.01 mg/ml butorphanol tartrate. b. Weigh mice. c. Administer anesthetic to mice; avoid rendering them unconscious (mice should appear 'drowsy'). Figures 3B, 3C , and 3E).
• Samples delivered for further analysis:
1. Purified transposon/transposase plasmids will be used in Protocol 2.
Confirmatory analysis plan
This replication attempt will perform the following statistical analyses listed below. First, the replication effect size will be computed and compared to the original effect size for each analysis. Second, the original effect size and the replication effect size will be combined into a single effect size using a meta-analytic approach and will be presented as a forest plot.
• Statistical Analysis of the Replication Data: i. C.B-17 wild-type mouse livers 6 days after delivery compared to C.B-17 wild-type mouse livers 30 days after delivery. ii. C.B-17 wild-type mouse livers 30 days after delivery compared to C.B-17 SCID/beige mouse livers 30 days after delivery.
• Two-way ANOVA comparing the percent of p21-positive cells in C.B-17 wildtype and C.B-17 SCID/beige mouse livers 6 and 30 days after stable delivery of Nras G12V/D38A . 3. Three-way ANOVA (2 × 2 × 2), comparing the percent of p16-positive cells in C. i. C.B-17 wild-type mouse livers 6 days after delivery compared to C.B-17 wild-type mouse livers 30 days after delivery. ii. C.B-17 wild-type mouse livers 30 days after delivery compared to C.B-17 SCID/beige mouse livers 30 days after delivery.
• Two-way ANOVA comparing the percent of p16-positive cells in C.B-17 wildtype and C.B-17 SCID/beige mouse livers 6 and 30 days after stable delivery of Nras G12V/D38A .
Known differences from the original study
The replication will only include evaluation of mice at days 6 and 30 post-injection. The original study also included evaluations at days 12 and 60 post-injection, as well as further analysis of liver tissue at 7 months post-injection. The replication is only comparing wild-type and SCID/beige mice; SCID mice were also included in the original study. The replication is including staining for Nras, p16, and p21. The original study also included pERK staining. All known differences in reagents are listed in the materials and reagents section above, as indicated in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
Each of the transposon and transposase plasmids will be verified for sequence identity and DNA integrity. All immunohistochemistry experiments will include isotype antibody controls and secondaryonly controls. All mice will be handled and housed in accordance with the Institutional Animal Care and Use Committee (IACUC) and the University of California-Davis. Exclusion criteria for successful hydrodynamic injections will be adhered to, as detailed above. According to the original authors, there is an expected failure rate of ∼20% for hydrodynamic injection. Therefore, we are including extra animals in each treatment group so that we can maintain the samples sizes necessary to achieve high statistical power (see 'Power calculations'). All of the raw data, including immunohistochemistry controls and complete mouse health records, will be uploaded to the project page on the OSF (https:// osf.io/82nfe/) and made publically available.
Protocol 2: determining the significance of CD4+ T lymphocyte cells in senescence surveillance
This protocol assesses the specific necessity for CD4 + T lymphocytes in immune surveillance of pre-malignant senescent hepatocytes. Oncogenic Nras G12V and non-oncogenic Nras G12V/D38A will be intrahepatically delivered to either wild-type or CD4 −/− mice via hydrodynamic injection. Senescence surveillance will be determined by measuring the clearance of Nras-positive cells from liver tissue sections 12 days following injection. This protocol replicates experiments reported in Figure 4A .
Sampling
1. These experiments will analyze a minimum of five mice per treatment group, for a total power of 94.6%.
• See 'Power calculations' section for details.
• In order to account for variability in hydrodynamic injections that might contribute to exclusion of study animals (estimated as a 20% failure rate by Kang et al.) , the initial starting sample size will be seven mice per treatment group. The inclusion of two additional animals will help ensure that at least five animals are available for analysis at the conclusion of the study.
2. Outline of experimental conditions: (tissue processed at 12 days post-injection).
• 14 female C57/BL6 (H-2b) wild-type mice (4-6 weeks old).
a. Seven mice injected with pPGK-SB13 + pT/CaggsNrasG12V. b. Seven mice injected with pPGK-SB13 + pT/CaggsNrasG12V/D38A.
• 14 female C57/BL6 CD4 −/− (4-6 weeks old).
Materials and reagents Procedure
1. Obtain 4-week-old female C57/BL6 wild-type and C57/BL6 CD4 −/− mice.
a. House mice in individual ventilated cages (IVC) that are specific pathogen free (SPF). Allow mice 1 week to acclimate to new housing prior to injection. b. Mice should be randomized into strain-based treatment and control groups and co-housed so that mice of the same strain receiving either Nras G12V or Nras G12V/D38A injections are housed together.
2. Using plasmids prepared in Protocol 1, randomly inject 5-week-old mice with transposon/transposase. Use detailed protocol provided in Protocol 1, as well as in the reference (Bell et al., 2007) . (compare to Figure 4A ).
Confirmatory analysis plan
• Statistical analysis of the replication data: 2. Note: In order to enable a direct comparison to the original data, an unpaired, two-tailed t-test (performed outside the framework of an ANOVA), comparing the percent of Nras-positive cells in wild-type mice injected with Nras G12V vs CD4 −/− mice injected with Nras G12V will also be performed.
Known differences from the original study
The replication will only include assessing genetically null CD4 −/− mice and wild-type controls at a time point of 12 days following intrahepatic injections. The original study also evaluated α-CD4 antibodydepleted mice, as well as genetically null and antibody-depleted CD8 −/− mice and genetically null Cd1d −/− mice. The original study also evaluated CD4 −/− mice and wild-type mice 7 months after injection. All known differences in reagents are listed in the materials and reagents section above, as indicated in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
Each of the transposon and transposase plasmids will be verified for sequence identity and DNA integrity. All immunohistochemistry experiments will include isotype antibody controls and secondaryonly controls. All mice will be handled and housed in accordance with the Institutional Animal Care and Use Committee (IACUC) and the University of California-Davis. Exclusion criteria for successful hydrodynamic injections will be adhered to, as detailed above. According to the original authors, there is an expected failure rate of ∼20% for hydrodynamic injection. Therefore, we are including extra animals in each treatment group so that we can maintain the samples sizes necessary to achieve high statistical power (see 'Power calcualtions'). All of the raw data, including immunohistochemistry controls and complete mouse health records will be uploaded to the project page on the OSF (https:// osf.io/82nfe/) and made publically available.
Power calculations
Protocol 1 Summary of original data from Figure 3B (Kang et al., 2011): Test family 2-way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05.
• Power calculations were performed with effects reported in original study using G*Power software (version 3.1.7) (Faul et al., 2007) .
• ANOVA F statistic calculated with GraphPad Prism 6.0.
• Partial η 2 calculated from Lakens (2013) .
Power calculations for replication Test family
• 2 tailed t test, difference between two independent means, Bonferroni's correction: alpha error = 0.025.
Power calculations (performed with G*Power software, version 3.1.7 [Faul et al., 2007] 
Registered report
Summary of original data from Figure 3C (Kang et al., 2011) :
Test family
2-way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05.
• Partial η 2 calculated from Lakens (2013).
Power calculations for replication Test family
Power calculations (performed with G*Power software, version 3.1.7 [Faul et al., 2007] ).
Summary of original data from Figure 3E (Kang et al., 2011) :
Test family 2-way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05.
• Power calculations were performed with effects reported in original study using G*Power software (version 3.1.7) (Faul et al., 2007) . • ANOVA F statistic calculated with GraphPad Prism 6.0.
Protocol 2
Summary of original data from Figure 4A (Kang et al., 2011) :
Test family 2-way ANOVA: Fixed effects, special, main effects, and interactions, alpha error = 0.05.
• Power calculations were performed with effects reported in original study using G*Power software (version 3.1.7) (Faul et al., 2007 *20 total (5/group) will be used to account for additional variance making the power 94.6%.
Registered report

Test family
Power calculations (Performed with G*Power software, version 3.1.7 [Faul et al., 2007] ).
